This study aims to establish a multicenter, prospective, observational registry database for type B aortic dissection based on approximately 60 regional sentinel hospitals across China. It develops a digital intelligent management system, formulates quality control indicators and data collection standards for type B aortic dissection, and optimizes the data quality control and evaluation system to realize comprehensive evaluation covering the entire diagnosis and treatment process and long-term prognosis. Artificial intelligence algorithms are adopted to construct a risk prediction model for adverse events, and auxiliary decision-making software is developed to identify potential risks of adverse events in a timely manner and establish an early warning system, ultimately reducing the in-hospital complication and mortality rates.
Relying on the National Quality Control Platform for Peripheral Vascular Intervention, this study further builds a national quality control platform for type B aortic dissection covering more than 5,000 hospitals nationwide by establishing a three-level quality control system. By integrating health administrative data, quality control data, electronic medical record data and clinical research data, a high-quality, multi-dimensional national quality control platform is constructed to support the sustainable development of quality control work. In addition, a clinical research collaboration network will be established to conduct in-depth evaluation of the national diagnosis and treatment patterns and outcomes of type B aortic dissection. Regular national training and assessment programs will be organized to improve the overall diagnosis and treatment capacity of medical institutions at all levels and reduce regional and institutional disparities in the quality of clinical care for the disease.
Aged between 18 and 80 years (inclusive);
Definite diagnosis of Stanford type B aortic dissection confirmed by three-dimensional CTA reconstruction;
Underwent TEVAR, including standalone TEVAR and hybrid procedures (only non-thoracotomy hybrid procedures);
Patients and their families signed informed consent and agreed to complete the 2-year full follow-up.
Presence of severe comorbidities or other diseases (e.g., severe chronic obstructive pulmonary disease, malignant tumors, dementia) or any physical condition that may affect patient compliance with this study;
A previous history of thoracic aortic surgery (including TEVAR, hybrid surgery, and open surgery);
Congenital aortic malformations;
Requiring concurrent intervention for cardiac or aortic sinus root lesions, or cardiac diseases that would alter the postoperative medication regimen;
Eligible patients without any exclusion criteria who received treatment for Stanford type B aortic dissection at each participating center
Cohort
Other
Endo vascular repair
Procedure/SurgeryThis is an observational study, and the intervention is the routine and standard care for patients.
Number of major adverse events
Major adverse events includes all-cause death and complications (endoleak, stent-graft induced new entry tear (SINE), aortic rupture, retrograde type A aortic dissection, aorta-related re-intervention, myocardial infarction, stroke, paraplegia, renal insufficiency, and dialysis requirement)
Number of participants with adverse events
Participants with aorta-related re-intervention or all-cause death
The change of distal true lumen diameter (unit: mm)
The change in distal true lumen (aorta below the stent graft) diameter before and after surgery
The change of distal false lumen diameter (unit: mm)
The change in distal false lumen (aorta below the stent graft) diameter before and after surgery
The number of false lumen thrombosis
The number of participants with false lumen thrombosis including complete thrombosis or partial thrombosis
Click on the lead sponsor to view all of their trials.
Chang Shu
Lead sponsor
China National Center for Cardiovascular Diseases
Sponsor institution
This trial is not recruiting at the moment. You can still explore other options:
